Pramipexole News and Research

RSS

NIH issues SBIR grant to Titan Pharmaceutical for PD treatment development

Titan Pharmaceuticals, Inc. today announced that the National Institutes of Health has awarded the company a grant under the Small Business Innovation Research program supporting the development of a long-term, non-fluctuating dopamine agonist treatment for Parkinson's disease. The first year award in the amount of $300,000 will be available to Titan starting August 1, 2010, and an additional $195,000 for the second year starting August 1, 2011 has been recommended subject to availability of funds and satisfactory progress of the project. The grant will be administered by the National Institute of Neurological Disorders and Stroke.

27 Jul 2010

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Of the three main types of oral drugs commonly added to levodopa therapy for patients with advanced Parkinson's disease, one might be the most effective, according to a new review.

9 Jul 2010

Teva reports 31% increase in non-GAAP net income for first-quarter 2010

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended March 31, 2010.

4 May 2010

Pramipexole ER uptake to be inhibited by availability of generic version

HealthLeaders-InterStudy and Fingertip Formulary find that the uptake of Boehringer Ingelheim's pramipexole ER, the once-daily formulation of its market leading dopamine agonist Mirapex that was approved earlier this month, will be inhibited by competition from generic pramipexole which became available earlier this year.

1 Apr 2010

FDA approves Mirapex ER tablets for signs and symptoms of idiopathic PD

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has approved once-daily Mirapex ER® (pramipexole dihydrochloride) extended-release tablets for the signs and symptoms of idiopathic Parkinson's disease, which includes early and advanced PD. PD is the second most common chronic neurological disorder in older adults after Alzheimer's. Parkinson's disease has no cure.

26 Mar 2010

Boehringer Ingelheim Pharmaceuticals receives FDA approval for Mirapex ER in treatment of early PD

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER® (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early idiopathic Parkinson's disease (PD). MIRAPEX ER is not indicated in advanced PD. Parkinson's disease is a chronic, slowly progressive and potentially debilitating neurological condition affecting nearly one million people in the U.S., with one person newly diagnosed every nine minutes.

22 Feb 2010

Reducing DA dosage causes acute withdrawal symptoms in Parkinson's patients

New research has shown that reducing the dosage of dopamine agonist (DA) drugs, a mainstay treatment for Parkinson's disease (PD), sometimes causes acute withdrawal symptoms similar to those reported by cocaine addicts -- including anxiety, panic attacks, depression, sweating, nausea, generalized pain, fatigue, dizziness and drug cravings. These symptoms can be severe, and are not alleviated by other PD medications.

12 Jan 2010

New systematic study for managing treatment-resistant bipolar depression

Depression in bipolar illness is often difficult to treat and life-threating. Frequently it fails to respond to standard treatments. In the current issue of Psychotherapy and Psychosomatics a new drug combination is suggested.

27 Oct 2009

Dopamine agonists trigger destructive behaviors

A new study conducted at Mayo Clinic reports that one in six patients receiving therapeutic doses of certain drugs for Parkinson's disease develops new-onset, potentially destructive behaviors, notably compulsive gambling or hypersexuality.

9 Apr 2009

Long-term effects of two common drugs for early Parkinson's similar

A study published online in the Archives of Neurology involving two common drugs used to treat early-stage Parkinson's disease shows that, while the drugs each have advantages and disadvantages, the overall impact tends to even out over a long period of treatment.

10 Mar 2009

New experimental treatment for Tourette's syndrome

The University of Rochester Medical Center (URMC) is leading a multi-center clinical research study of a new experimental treatment for Tourette's syndrome.The study will examine whether or not a drug that alters the chemical activity in the brain can alleviate the symptoms of the disease.

2 Dec 2008

Barr Labs to settle Mirapex and Aggrenox patent challenges

Barr Pharmaceuticals, Inc announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex product.

12 Aug 2008

Barr announces favorable ruling in Mirapex patent challenge

Barr Pharmaceuticals, Inc. has announced that U.S. District Court for Delaware has ruled in favor of its subsidiary, Barr Laboratories, Inc., in the challenge of the patent listed by Boehringer Ingelheim Pharmaceuticals, Inc. in connection with Boehringer Ingelheim's Mirapex(R) Tablets (pramipexole dihydrochloride) 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg.

26 Jun 2008

Barr receives approval for generic Mirapex tablets

Barr Pharmaceuticals, Inc. has announced that its subsidiary, Barr Laboratories, Inc., has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Boehringer Ingelheim Pharmaceuticals, Inc.'s Mirapex Tablets (Pramipexole Dihydrochloride) 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg.

20 Feb 2008

People with early Parkinson's more likely to develop hallucinations, sleepiness and swelling

People with early Parkinson's disease report a higher than anticipated development or worsening of hallucinations, sleepiness, and swelling.

10 Jul 2007

Researchers look at whether creatine slows progression of Parkinson's disease

Researchers at the University of Rochester Medical Center are leading one of the largest clinical trials ever for Parkinson's disease.

25 Mar 2007

Therapy for restless legs may trigger compulsive gambling

Compulsive gambling with extreme losses -- in two cases, greater than $100,000 -- by people without a prior history of gambling problems has been linked to a class of drugs commonly used to treat the neurological disorder restless legs syndrome (RLS).

11 Feb 2007

Dopamine drug leads to new neurons and recovery of function in Parkinson's

In preliminary results, researchers have shown that a drug which mimics the effects of the nerve-signaling chemical dopamine causes new neurons to develop in the part of the brain where cells are lost in Parkinson's disease (PD).

5 Jul 2006

Dopamine drug may lead to new ways of treating Parkinson's and other neurodegenerative diseases

Researchers have shown that a drug which mimics the effects of the nerve-signaling chemical dopamine causes new neurons to develop in the part of the brain where cells are lost in Parkinson's disease

4 Jul 2006

First trial of pramipexole for the treatment of fibromyalgia

The mechanism of fibromyalgia, a chronic illness characterized by muscle pain, fatigue, and sleep disturbances, is unknown and medications used to treat it (such as antidepressants, antiepileptics, muscle relaxants, antiinflammatories, sedative hypnotics, pain relievers and nutriceuticals) have had limited success.

28 Jul 2005